In addition, widespread microglial activation has been demonstrated in secondary progressive MS (SPMS; Kutzelnigg et al., 2005), suggesting that ACTH may be of benefit in the progressive phase of MS; however, this has not been studied in clinical trials. This evidence concerns the gene POMC and myeloid sarcoma.